Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
An eye drug biotech banks $118M and stocks its executive suite
1+ hour, 7+ min ago (662+ words) Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency. Claris Biotherapeutics has netted $118 million and hired new chief…...
From confidence to capital: Positioning biotech for the next growth cycle
1+ day, 3+ hour ago (148+ words) BioPharma Dive From confidence to capital: Positioning biotech for the next growth cycle This is the year that biotech’s confidence returned. Conversations at two of 2026’s biggest biotech conferences, DIA China in Shanghai and BIO International Convention in San Diego,…...
Scribe secures $129M in a rare gene editing IPO
4+ day, 11+ hour ago (280+ words) The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotech companies that have gone public in 2026. Scribe Therapeutics has raised close to $129 million in…...
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
6+ day, 20+ hour ago (304+ words) The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic. Dimension, a young venture capital firm at the vanguard of biotechnology’s…...
Braveheart, Attovia join next wave of biotech IPOs
1+ week, 5+ day ago (316+ words) The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs. Attovia Therapeutics and Braveheart Bio revealed on Tuesday plans to go public, where they’ll…...
Judge orders Apple Tree partner to forfeit oversight of venture fund
1+ week, 6+ day ago (342+ words) The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing. Rybolovlev's family trust originally became entangled with ATP in 2012 by agreeing to fund up to $1.5 billion of…...
Biotech startup funding gap widens despite rebound in VC investment
2+ week, 1+ day ago (570+ words) Nearly 70 venture-backed biotechnology startups raised more than $9.1 billion between January and June, according to BioPharma Dive data, but the majority already had drugs in testing. Biotechnology venture capital funding continued a multi-year surge in the first half of 2026, as strong…...
Gene editing developer Scribe plots an IPO
3+ week, 21+ hour ago (376+ words) The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026. “Large pharma is recognizing that this has the potential to be the future of medicine,” Oakes told BioPharma…...
A PureTech startup banks $180M for a new IPF drug
3+ week, 4+ day ago (377+ words) Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche’s Esbriet. Celea Therapeutics, a biotechnology startup testing a next-generation treatment for idiopathic pulmonary fibrosis, said in a…...
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs
1+ mon, 5+ day ago (599+ words) The same factors that ignited the last IPO boom may drive an acceleration in new biotech stock offerings in the second half of 2026. SAN DIEGO — Expect initial public offerings for biotechnology companies to continue to pop in the second half…...